Amicus Therapeutics, Inc. (FOLD) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Philadelphia, PA, United States. Le PDG actuel est Bradley L. Campbell.
FOLD a date d'introduction en bourse 2007-05-31, 499 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $4.54B.
Amicus Therapeutics, Inc. is a biotechnology company headquartered in Philadelphia that specializes in discovering, developing, and commercializing medicines for rare genetic diseases. The company's lead commercial product is Galafold, an oral precision medicine approved for treating adults with Fabry disease who carry amenable galactosidase alpha gene variants. Its pipeline includes AT-GAA for Pompe disease, AT-GTX-502, a gene therapy in Phase 1/2 development for CLN3 disease, and a gene therapy program targeting CDKL5 deficiency. Amicus maintains strategic collaborations with major research institutions including Nationwide Children's Hospital, University of Pennsylvania, and GlaxoSmithKline to advance its development programs. Founded in 2002, the company is focused on addressing significant unmet medical needs in the rare disease community.
